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Abstract  
Introduction: There are multiple new systemic therapies for patients with metastatic melanoma, including 
vemurafenib and ipilimumab. Because of this, more patients will be exposed to multiple medicines during 
their treatment course. Here we present the case of a successful rechallenge with vemurafenib and concurrent 
corticosteroids in a patient with vemurafenib responsive metastatic melanoma and vemurafenib induced liver 
dysfunction thought to be related to previous treatment of ipilimumab.  
Presentation of case: A 60-year-old woman presented with metastatic melanoma to her liver and lymph 
nodes with normal liver function tests (LFTs) and was started on ipilimumab. With rapid disease progression 
despite ipilimumab, treatment was switched to vemurafenib. She experienced quick and good regression in 
her disease burden but subsequently experienced a grade 4 elevation in her LFTs, which res olved with a 
corticosteroid taper. Her disease responded well to a vemurafenib rechallenge at a reduced dose; however, 
she experienced another increase in her LFTs.  By administering vemurafenib with corticosteroids 
concurrently, she achieved good tumor shrinkage without liver dysfunction.  
Conclusion: While not all drug related liver toxicity has been shown to be responsive to corticosteroids, for 
patients previously treated with ipilimumab who experience elevated LFTs while on vemurafenib, 
re-challenging with a reduced dose of vemurafenib and concurrent corticosteroids treatment may be tried 
with the goal of maintaining good clinical efficacy and controlling liver dysfunction. 
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Introduction 
Multiple systemic treatments for metastatic 
melanoma have recently been approved, 
including vemurafenib and ipilimumab, with 
many more in development. As more patients 
with metastatic melanoma receive treatment 
with these medicines, the number of patients 
exposed to multiple new systemic therapies at 
some point during their treatment course will 
increase, with the potential for an emerging 
adverse event profile associated with 
temporally separate exposures. We present the 
case of a 60 year old female with vemurafenib 
responsive metastatic melanoma and a 
previous exposure to ipilimumab who 
developed a Grade 4 hepatitis while on 
vemurafenib who was successfully managed 
with concurrent vemurafenib and 
corticosteroid treatment. 
Case Report 
A 60 year old Caucasian female with a past 
medical history of hypothyroidism was 
diagnosed with melanoma in situ in 2008, 
excised with a 1 cm margin. Upon resection, 
the surgical margins were clear. In 2009, she 
had a recurrence in her left upper flank. 
Restaging positron emission 
tomography/computed tomography (PET/CT) 
scan demonstrated multiple nodules in the left 
flank and in the axilla. She subsequently 
underwent full left axillary lymphadenectomy 
and adjuvant XRT, followed by high dose 
adjuvant Interferon therapy for resected stage 
IIIb disease. Her follow up PET/CT scan 6 
months from the completion of interferon was 
unremarkable but the 12 months post 
interferon PET/CT scan showed multiple liver 
and subcutaneous nodules. Biopsy of skin and 
genetic analysis revealed BRAF V600E 
mutation positive metastatic melanoma. The 
patient was initially started on ipilimumab 3 
mg/kg IV every 3 weeks, hoping for 
sustainable response given her relatively 
asymptomatic disease. Although she did not 
experience any significant side effects, after 2 
cycles of treatment her disease dramatically 
progressed and she became symptomatic. 
Vemurafenib 960 mg BID was initiated 1 week 
after her last dose of ipilimumab with good 
clinical response. 3 weeks after starting 
treatment with vemurafenib, the patient 
developed a moderate skin rash and her dose 
was reduced to 720mg BID. Despite this 
reduction, a grade 3 elevation (AST=504 IU, 
ALT=328 IU) in her LFTs was detected at 6 
weeks into treatment with vemurafenib 720 mg 
BID. Despite discontinuation of vemurafenib, 
her LFTs continued to increase to grade 4 
(AST=828 IU, ALT=504) 3 days later. 
Abdominal CT at this point showed a 
significant decrease in the size of her liver 
lesions compared to her scan 3 weeks ago. 
Given previous treatment with ipilimumab, an 
autoimmune hepatitis was suspected and 
prednisone 1 mg/kg was started. Immediately 
after starting prednisone, her LFTs started to 
decrease and normalized at 3 weeks after her 
first steroid dose. Two months after 
discontinuation of vemurafenib, she presented 
with rapidly increasing painful skin nodules. 
With this disease progression, vemurafenib 
was restarted at 720 mg BID, however, her 
LFTs rose rapidly within 2 weeks to grade 3 
level (AST=384 IU, ALT=253 IU). Even with 
a short course treatment (14 days), her 
subcutaneous nodules showed quick shrinkage 
with significant pain relief.  Stopping 
vemurafenib and starting prednisone 1 mg/kg 
returned her LFTs to baseline within 3 weeks. 
Unfortunately, 7 weeks after the second 
discontinuation of vemurafenib, her nodules 
started to increase again with moderate pain, 
so this time vemurafenib 480 mg BID with 
concurrent 20 mg prednisone was prescribed. 
Her LFTs increased during the first week 
(AST=356 IU, ALT=180 IU), again with 
dramatic clinical response noted in tumor 
shrinkage, leading us to stop vemurafenib 
treatment again and increase her prednisone 
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dose from 20 mg to 40 mg. This brought her 
LFTs back down (AST=60 IU, ALT=110). At 
her next appointment, the decision was made 
to start her on vemurafenib 240 mg with 40 mg 
of prednisone, as her melanoma had remained 
responsive to vemurafenib throughout her 
clinical course. Her tumor again showed quick 
response and this time the patients LFTs 
remained stable at a grade 1 level. Since 
starting this last regimen, the patient was able 
to wean her prednisone dose to 10 mg once a 
day over 4 weeks with no significant elevation 
of her LFTs and her disease continued to 
demonstrate good clinical response to 
vemurafenib.  
Eight months from the first dose of 
vemurafenib, her disease progressed and she 
succumbed to death 2 months into this 
progression. Her vemurafenib dose was 
increased to 720 mg at progression but she did 
not experienced liver dysfunction with 
concurrent low dose prednisone. See Figure 1 
for the patient’s LFTs over time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 LFTs over time. The patient did not drink alcohol nor partake in any behaviors risky for infection 
during her therapy with either ipilimumab or vemurafenib. A liver biopsy was not performed due to 
presumed lack of clinical yield. 
 
Discussion 
Hepatitis and elevated liver function tests are 
common adverse events associated with 
medicine administration. The differential 
diagnosis of elevated LFTs includes viral, 
autoimmune, inherited metabolic disorders, 
endocrine disorders, ischemia, cholestatic and 
toxic causes. Our patient had a negative 
hepatitis viral panel. Liver ultrasound did not 
visualize significant disease progression or 
cholestatic processes. Other than her history of 
hypothyroidism, the patient did not have signs, 
symptoms or a history of inherited or acquired 
metabolic or endocrine disorders. The timing 
of her LFT elevations, along with the negative 
workup for other causes, led us to suspect an 
autoimmune hepatitis, likely related to her 
treatment with previous ipilimumab. In the 
case presented, the contribution of either drug 
to the adverse event cannot be reliably ruled 
out. The timing of the events suggested drug 
toxicity from vemurafenib as the cause of her 
liver dysfunction, but simple discontinuation 
of vemurafenib did not resolve the liver 
dysfunction in this case.  
Immune-related adverse events associated 
with ipilimumab therapy have been reported 
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up to two years after discontinuation of 
therapy [1]. Both discontinuation of 
ipilimumab and administration of 
corticosteroids induce resolution of 
autoimmune hepatitis, with a median time to 
resolution of 3.1 to 4.6 weeks when treated 
with corticosteroids with only 1.9% of patients 
requiring additional immunosuppressive 
therapy with either infliximab or 
mycophenolate mofetil [2]. In this presented 
case the response to steroids is suggestive of a 
contribution from an auto-immune related 
adverse event. There  are reports of liver 
dysfunction associated with imatinib, 
responsive to corticosteroids [3] but there is a 
report of steroid refractory hepatotoxicity 
related to treatment with gefitinib [4]. To our 
knowledge, there are not similar case reports 
involving vemurafenib in the literature. 
In previously untreated patients, treatment 
with ipilimumab/dacarbazine combination 
therapy has demonstrated an increased median 
survival time compared to monotherapy 
dacarbazine monotherapy [5]. In patients 
previously treated, treatment with ipilimumab 
and gp100 vaccine has been shown to increase 
median survival compared to those patients 
only receiving the gp100 vaccine [1]. In 
treatment naïve patients with BRAF mutation 
positive metastatic melanoma, treatment with 
vemurafenib is associated with an increase in 
progression free survival over those patients 
treated with dacarbazine [6]. Patients with 
previously treated BRAF mutation positive 
melanoma who subsequently undergo 
treatment with vemurafenib demonstrate a 
median survival of 15.9 months in a phase 2 
trial [7]. 
In recent ipilimumab studies, 2.1% of 
patients experienced elevations in their liver 
function tests when treated with ipilimumab 
and gp100 versus 3.8% of patients treated with 
ipilimumab alone [1]. Robert et al. report an 
alanine aminotransferase elevation in 29.1% of 
patients treated with ipilimumab and 
dacarbazine but an elevation in only 4.4% of 
patients treated with dacarbazine monotherapy 
[5]. The relatively low incidence of 
auto-immune hepatitis associated with 
ipilimumab monotherapy and the greatly 
increased incidence of autoimmune hepatitis 
associated with ipilimumab/dacarbazine 
combination therapy indicates the potential for  
ipilimumab combination therapy to have a 
greater propensity to induce autoimmune 
hepatitic reactions than ipilimumab 
monotherapy. 
Vemurafenib has been associated with liver 
toxicity, with abnormal liver function studies 
occurring in 23 of 132 (17%) patients while on 
vemurafenib, with grade 3 and 4 reactions 
occurring in 8 (6%) and 4 (3%) patients 
respectively [7]. Generally, hepatotoxicity due 
to vemurafenib resolves with discontinuation 
of therapy [7]. 
Corticosteroids have become the standard 
treatment for immune-related adverse events 
(irAEs) associated with ipilimumab and their 
use in various irAEs was detailed by Weber in 
2012 [8]. The important of corticosteroid 
treatment of irAEs is suggested by a case of 
fulminant autoimmune hepatitis resulting in 
death in which the administration of 
corticosteroids was delayed [2]. Prophylactic 
use of corticosteroids, however, has not been 
found to be efficacious in preventing 
ipilimumab related irAEs [9].  Recent studies 
indicate that treatment of ipilimumab-related 
irAEs with corticosteroids do not affect the 
efficacy of treatment with ipilimumab [10, 11]. 
These results demonstrate the feasibility and 
importance of treating through side effects 
associated with ipilimumab with 
corticosteroids in a timely manner. 
Conclusion 
The frequency that patients with metastatic 
melanoma get exposed to both ipilimumab and 
vemurafenib during their treatment course will 
likely increase, because as clinicians we want 
to utilize all available therapies to treat 
metastatic melanoma as indicated. Currently, a 
prospective, multicenter, phase 1-2 trial, 
 Radack K, et al. American Journal of Cancer Case Reports 2013, 1:60-65 
 
Ivy Union Publishing | http: //www.ivyunion.org May 14, 2013 | Volume 1 | Issue 1  
Page 5 of 6 
ClinicalTrials.gov number, NCT01400451, is 
investigating the safety and efficacy of 
concurrent therapy with ipilimumab and 
vemurafenib for BRAF V600E mutant 
metastatic melanoma. Hepatotoxicity with 
combination of vemurafenib and ipilimumab 
with this phase 1 trial was reported as a 
correspondence in a recent New England 
Journal of Medicine
12
. Practitioners should 
monitor patients carefully, including their liver 
function tests, during vemurafenib treatment in 
a patient who has previously been treated with 
ipilimumab due to the potential for liver 
dysfunction. While not all drug related liver 
toxicity has been shown to be responsive to 
corticosteroids, for patients previously treated 
with ipilimumab who experience elevated 
LFTs while on vemurafenib, re-challenging 
with a reduced dose of vemurafenib and 
concurrent corticosteroids treatment may be 
tried with the goal of maintaining good 
clinical efficacy and controlling liver injury.  
Consent 
The patient’s spouse has given informed 
consent to the publication of this report. 
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